Viamet Pharmaceutical, a Research Triangle park biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, closed a $4 million Series A financing round.(FINANCING)
Publication Date: 01-JUL-07
Publication Title: BT Catalyst
Format: Online
Company: Intersouth Partners~Finance

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Viamet Pharmaceutical, a Research Triangle park biotechnology company...



More articles from BT Catalyst
Entegrion, a Research Triangle park biotechnology spin-out of Universi..., July 01, 2007
LaamScience, a Research Triangle park-based company founded on a disco..., July 01, 2007
The Piedmont Angel Network Two (PAN Two), a structured, committed capi..., July 01, 2007
OncoMethylome Sciences, a molecular diagnostics company based in Belgi..., July 01, 2007
Durham-based Argos Therapeutics has raised $5 million in a three-year ..., July 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.